Lakefront Biotherapeutics (GLPGF) Gross Profit Growth (3y) (2024 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Gross Profit Growth (3y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 11.87% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 6.47% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 9.20% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 10.09% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 77.42% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 28.75% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 59.77% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 1.69% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -61.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -61.35% |
| Mar 31, 2026 | -67.81% |
| Dec 31, 2025 | -474.81% |
| Sep 30, 2025 | -19.46% |
| Jun 30, 2025 | -21.90% |
| Mar 31, 2025 | -24.51% |
| Dec 31, 2024 | 33.81% |
| Sep 30, 2024 | -24.65% |
| Jun 30, 2024 | -29.21% |
| Mar 31, 2024 | -22.05% |